Search Results - "Buderath, P"

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial by Ray-Coquard, I., Leary, A., Pignata, S., Cropet, C., González-Martín, A., Marth, C., Nagao, S., Vergote, I., Colombo, N., Mäenpää, J., Selle, F., Sehouli, J., Lorusso, D., Guerra Alia, E.M., Bogner, G., Yoshida, H., Lefeuvre-Plesse, C., Buderath, P., Mosconi, A.M., Lortholary, A., Burges, A., Medioni, J., El-Balat, A., Rodrigues, M., Park-Simon, T.-W., Dubot, C., Denschlag, D., You, B., Pujade-Lauraine, E., Harter, P.

“…In the PAOLA-1/ENGOT-ov25 primary analysis, maintenance olaparib plus bevacizumab demonstrated a significant progression-free survival (PFS) benefit in newly…”
Get full text

Depression and anxiety in women with malignant ovarian germ cell (MOGCT) and sex cord stromal tumors (SCST): an analysis of the AGO-CORSETT database by Bossart, M., Plett, H., Krämer, B., Braicu, E., Czogalla, B., Klar, M., Singer, S., Mayr, D., Staebler, A., du Bois, A., Kommoss, S., Link, T., Burges, A., Heitz, F., Grube, M., Trillsch, F., Harter, P., Wimberger, P., Buderath, P., Hasenburg, A.

“…Introduction The intention of this study was to evaluate the level of anxiety and depression of malignant ovarian germ cell (MOGCT) and sex cord stromal tumors…”
Get full text

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer by Ray-Coquard, Isabelle, Pautier, Patricia, Pignata, Sandro, Pérol, David, González-Martín, Antonio, Berger, Regina, Fujiwara, Keiichi, Vergote, Ignace, Colombo, Nicoletta, Mäenpää, Johanna, Selle, Frédéric, Sehouli, Jalid, Lorusso, Domenica, Guerra Alía, Eva M, Reinthaller, Alexander, Nagao, Shoji, Lefeuvre-Plesse, Claudia, Canzler, Ulrich, Scambia, Giovanni, Lortholary, Alain, Marmé, Frederik, Combe, Pierre, de Gregorio, Nikolaus, Rodrigues, Manuel, Buderath, Paul, Dubot, Coraline, Burges, Alexander, You, Benoît, Pujade-Lauraine, Eric, Harter, Philipp

“…When used as maintenance therapy, the PARP inhibitor olaparib provided a significant progression-free survival benefit in women with ovarian cancer who had a…”
Get full text

Minimally invasive surgery for cervical cancer : Consequences of the LACC study by Buderath, P, Kimmig, R

Get full text

1524P Epidemiology and demography of gynecological sarcoma: Results of the prospective intergroup registry for gynecological sarcoma REGSA (NOGGO RU1) by Roser, E., Noack, A-S., Zocholl, D., Kommoss, S., Harter, P., Kalder, M., Egger, E.K., Buderath, P., Marth, C., Ulrich, U., Klar, M., Weigel, M., Traub, L., Strauß, H-G., Hanker, L., Pölcher, M., Wimberger, P., Beck, F., Pietzner, K., Sehouli, J.

Get full text

876P The effect of surgical techniques on sexuality and global quality of life (Qol) in women with ovarian germ cell (OGCT) and sex cord stromal tumours (SCST): An analysis of the AGO-CORSETT database by Hasenburg, A., Plett, H., Krämer, B., Braicu, E., Czogalla, B., Bossart, M., Singer, S., Mayr, D., Staebler, A., du Bois, A., Kommoss, S., Link, T., Burges, A., Heitz, F., Keul, J., Trillsch, F., Harter, P., Wimberger, P., Buderath, P., Klar, M.

Get full text

812MO Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial by Colombo, N., Gantzer, J., Ataseven, B., Cropet, C., Scambia, G., Herrero, A., Sevelda, P., Kobayashi, H., Vuylsteke, P., Mirza, M.R., Priou, F., Buderath, P., Pisano, C., Lainez, N., Guillemet, C., Burges, A., Sverdlin, R., El-Balat, A., Raban, N., Ray-Coquard, I.L.

Get full text

Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev by Fujiwara, K., Harter, P., Leary, A., Perol, D., Pignata, S., González-Martín, A., Petru, E., van Nieuwenhuysen, E., Colombo, N., Mäenpää, J., Selle, F., de Gregorio, N., Lorusso, D., Guerra Alia, E.M., Lefeuvre-Plesse, C., Buderath, P., Lortholary, A., Burges, A., Pujade-Lauraine, E., Ray-Coquard, I.L.

Get full text

Digital Immune-Related Gene Expression Signatures In High-Grade Serous Ovarian Carcinoma: Developing Prediction Models For Platinum Response by Mairinger, Fabian, Bankfalvi, Agnes, Schmid, Kurt Werner, Mairinger, Elena, Mach, Pawel, Walter, Robert Fh, Borchert, Sabrina, Kasimir-Bauer, Sabine, Kimmig, Rainer, Buderath, Paul

“…Response to platinum-based therapy is a major prognostic factor in high-grade serous ovarian cancer (HGSOC). While the exact mechanisms of platinum-resistance…”
Get full text

Minimalinvasive Chirurgie des Zervixkarzinoms: Konsequenzen aus der LACC-Studie by Buderath, P., Kimmig, R.

Get full text

Ovarialkarzinom: Diagnostik und Therapie by Buderath, P., Kimmig, R.

“…Zusammenfassung Das Ovarialkarzinom ist das Genitalmalignom mit der höchsten Sterblichkeit. Da charakteristische Frühsymptome fehlen, erfolgt die Diagnose…”
Get full text

EMT-assoziierte zirkulierende Tumorzellen im Blut von Ovarialkarzinompatientinnen und deren Anreicherung unter platinbasierter Chemotherapie by Kuhlmann, JD, Chebouti, I, Kasimir-Bauer, S, Buderath, P, Hauch, S, Kimmig, R, Wimberger, P

“…Abstract only…”
Get full text

ERCC1-positive zirkulierende Tumorzellen im Blut von Ovarialkarzinompatientinnen als neuer prädiktiver Biomarker für Platinresistenz by Kuhlmann, JD, Bankfalvi, A, Keller, T, Schöler, S, Aktas, B, Buderath, P, Hauch, S, Kimmig, R, Kasimir-Bauer, S, Wimberger, P

“…Abstract only…”
Get full text

Minimalinvasive Chirurgie des Zervixkarzinoms by Buderath, P Dr, Kimmig R Prof Dr Dr med

Get full text

Peritoneale mesometriale Resektion (PMMR) als Kompartiment-basierte Operation: Technik beim „intermediate/high risk“ Endometriumkarzinom by Kimmig, R., Buderath, P., Aktas, B., Heubner, M.

“…Zusammenfassung Die Anwendung des Prinzips der Kompartiment-basierten Chirurgie auf die Therapie des Endometriumkarzinoms scheint auf der Grundlage der…”
Get full text